New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 250 [iu];   - powder for infusion - 250 iu - active: eftrenonacog alfa 250 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 3000 [iu];   - powder for infusion - 3000 iu - active: eftrenonacog alfa 3000 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 500 [iu];   - powder for infusion - 500 iu - active: eftrenonacog alfa 500 [iu]   excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 150 [iu] (11 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 150 [iu] (11 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 225 [iu] (16.5 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 225 [iu] (16.5 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 300 [iu] (22 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 300 [iu] (22 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 450 [iu] (33 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 450 [iu] (33 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 75 [iu] (5.5 mcg) - solution for injection - 600 iu/ml - active: follitropin alfa 75 [iu] (5.5 mcg) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate dihydrate phosphoric acid poloxamer sucrose water for injection - in adult men: bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 1000 [iu];   - powder for infusion - 1000 iu - active: efmoroctocog alfa 1000 [iu]   excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 1500 [iu];   - powder for infusion - 1500 iu - active: efmoroctocog alfa 1500 [iu]   excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.